Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Wiener Medizinische Wochenschrift 5-6/2021

29.01.2021 | main topic

New therapeutic options for bone diseases

verfasst von: MD Assoc. Prof. PD Roland Kocijan, MD Judith Haschka, MD Julia Feurstein, MD Assoc. Prof. PD Jochen Zwerina

Erschienen in: Wiener Medizinische Wochenschrift | Ausgabe 5-6/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

In recent years, new treatment options for both common and rare bone diseases have become available. The sclerostin antibody romosozumab is the most recently approved drug for the therapy of postmenopausal osteoporosis. Its anabolic capacity makes it a promising treatment option for severe osteoporosis. Other sclerostin antibodies for the treatment of rare bone diseases such as osteogenesis imperfecta are currently being investigated. For rare bone diseases such as X‑linked hypophosphatemia (XLH) and hypophosphatasia (HPP), specific therapies are now also available, showing promising data in children and adults with a severe disease course. However, long-term data are needed to assess a sustained benefit for patients.

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
1.
Zurück zum Zitat Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020. Handbook of experimental pharmacology. 2020. Kocijan R, Klaushofer K, Misof BM. Osteoporosis therapeutics 2020. Handbook of experimental pharmacology. 2020.
2.
Zurück zum Zitat Padhi D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26. PubMed Padhi D, et al. Single-dose, placebo-controlled, randomized study of AMG 785, a sclerostin monoclonal antibody. J Bone Miner Res. 2011;26(1):19–26. PubMed
3.
Zurück zum Zitat MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. PubMedPubMedCentral MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: components, mechanisms, and diseases. Dev Cell. 2009;17(1):9–26. PubMedPubMedCentral
4.
Zurück zum Zitat Brunkow ME, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89. PubMedPubMedCentral Brunkow ME, et al. Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein. Am J Hum Genet. 2001;68(3):577–89. PubMedPubMedCentral
5.
Zurück zum Zitat McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. PubMed McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412–20. PubMed
6.
Zurück zum Zitat Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43. Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532–43.
7.
Zurück zum Zitat Cosman F, et al. Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res. 2018;33(8):1407–16. PubMed Cosman F, et al. Romosozumab FRAME study: a post hoc analysis of the role of regional background fracture risk on nonvertebral fracture outcome. J Bone Miner Res. 2018;33(8):1407–16. PubMed
8.
Zurück zum Zitat Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27. PubMed Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417–27. PubMed
9.
Zurück zum Zitat Lewiecki EM, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93. PubMed Lewiecki EM, et al. A phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183–93. PubMed
10.
Zurück zum Zitat Miyauchi A, et al. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019;14(1):59. PubMedPubMedCentral Miyauchi A, et al. Increased bone mineral density for 1 year of romosozumab, vs placebo, followed by 2 years of denosumab in the Japanese subgroup of the pivotal FRAME trial and extension. Arch Osteoporos. 2019;14(1):59. PubMedPubMedCentral
11.
Zurück zum Zitat Lewiecki EM, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419–28. PubMed Lewiecki EM, et al. One year of romosozumab followed by two years of denosumab maintains fracture risk reductions: results of the FRAME extension study. J Bone Miner Res. 2019;34(3):419–28. PubMed
12.
13.
Zurück zum Zitat Ebina K, et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020;140:115574. PubMed Ebina K, et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone. 2020;140:115574. PubMed
14.
Zurück zum Zitat Langdahl BL, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–94. PubMed Langdahl BL, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585–94. PubMed
16.
Zurück zum Zitat Sinder BP, et al. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73–80. PubMedPubMedCentral Sinder BP, et al. Sclerostin antibody improves skeletal parameters in a Brtl/+ mouse model of osteogenesis imperfecta. J Bone Miner Res. 2013;28(1):73–80. PubMedPubMedCentral
17.
Zurück zum Zitat Sinder BP, et al. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone. 2015;71:115–23. PubMed Sinder BP, et al. Rapidly growing Brtl/+ mouse model of osteogenesis imperfecta improves bone mass and strength with sclerostin antibody treatment. Bone. 2015;71:115–23. PubMed
18.
Zurück zum Zitat Sinder BP, et al. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int. 2014;25(8):2097–107. PubMedPubMedCentral Sinder BP, et al. Adult Brtl/+ mouse model of osteogenesis imperfecta demonstrates anabolic response to sclerostin antibody treatment with increased bone mass and strength. Osteoporos Int. 2014;25(8):2097–107. PubMedPubMedCentral
19.
Zurück zum Zitat Cardinal M, et al. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone. 2019;124:137–47. PubMed Cardinal M, et al. Sclerostin antibody reduces long bone fractures in the oim/oim model of osteogenesis imperfecta. Bone. 2019;124:137–47. PubMed
20.
Zurück zum Zitat Roschger A, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone. 2014;66:182–8. PubMed Roschger A, et al. Effect of sclerostin antibody treatment in a mouse model of severe osteogenesis imperfecta. Bone. 2014;66:182–8. PubMed
21.
Zurück zum Zitat Glorieux FH, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis Imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32(7):1496–504. PubMed Glorieux FH, et al. BPS804 anti-sclerostin antibody in adults with moderate osteogenesis Imperfecta: results of a randomized phase 2a trial. J Bone Miner Res. 2017;32(7):1496–504. PubMed
22.
Zurück zum Zitat Seefried L, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest. 2017;127(6):2148–58. PubMedPubMedCentral Seefried L, et al. Efficacy of anti-sclerostin monoclonal antibody BPS804 in adult patients with hypophosphatasia. J Clin Invest. 2017;127(6):2148–58. PubMedPubMedCentral
23.
Zurück zum Zitat Raimann A, Mindler G, Kocijan R, Bekes K, Zwerina J, Haeusler G, et al. Multidisciplinary patient care in X‑linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr. 2020;170:116–23. PubMedPubMedCentral Raimann A, Mindler G, Kocijan R, Bekes K, Zwerina J, Haeusler G, et al. Multidisciplinary patient care in X‑linked hypophosphatemic rickets: one challenge, many perspectives. Wien Med Wochenschr. 2020;170:116–23. PubMedPubMedCentral
24.
Zurück zum Zitat Che H, et al. Impaired quality of life in adults with X‑linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325–33. PubMed Che H, et al. Impaired quality of life in adults with X‑linked hypophosphatemia and skeletal symptoms. Eur J Endocrinol. 2016;174(3):325–33. PubMed
25.
Zurück zum Zitat Skrinar A, et al. The lifelong impact of X‑linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321–34. PubMedPubMedCentral Skrinar A, et al. The lifelong impact of X‑linked hypophosphatemia: results from a burden of disease survey. J Endocr Soc. 2019;3(7):1321–34. PubMedPubMedCentral
26.
Zurück zum Zitat Chesher D, et al. Outcome of adult patients with X‑linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41(5):865–76. PubMedPubMedCentral Chesher D, et al. Outcome of adult patients with X‑linked hypophosphatemia caused by PHEX gene mutations. J Inherit Metab Dis. 2018;41(5):865–76. PubMedPubMedCentral
27.
Zurück zum Zitat Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X‑linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–55. PubMedPubMedCentral Haffner D, et al. Clinical practice recommendations for the diagnosis and management of X‑linked hypophosphataemia. Nat Rev Nephrol. 2019;15(7):435–55. PubMedPubMedCentral
28.
Zurück zum Zitat Connor J, et al. Conventional therapy in adults with X‑linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab. 2015;100(10):3625–32. PubMedPubMedCentral Connor J, et al. Conventional therapy in adults with X‑linked hypophosphatemia: effects on enthesopathy and dental disease. J Clin Endocrinol Metab. 2015;100(10):3625–32. PubMedPubMedCentral
29.
Zurück zum Zitat Carpenter TO, et al. A clinician’s guide to X‑linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8. PubMedPubMedCentral Carpenter TO, et al. A clinician’s guide to X‑linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381–8. PubMedPubMedCentral
30.
Zurück zum Zitat Fratzl-Zelman N, et al. Alterations of bone material properties in adult patients with X‑linked hypophosphatemia (XLH). J Struct Biol. 2020;211(3):107556. PubMed Fratzl-Zelman N, et al. Alterations of bone material properties in adult patients with X‑linked hypophosphatemia (XLH). J Struct Biol. 2020;211(3):107556. PubMed
31.
Zurück zum Zitat Schindeler A, Biggin A, Munns CF. Clinical evidence for the benefits of burosumab therapy for X‑linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne). 2020;11:338. Schindeler A, Biggin A, Munns CF. Clinical evidence for the benefits of burosumab therapy for X‑linked hypophosphatemia (XLH) and other conditions in adults and children. Front Endocrinol (Lausanne). 2020;11:338.
32.
Zurück zum Zitat Imel EA, et al. Burosumab versus conventional therapy in children with X‑linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416–27. PubMedPubMedCentral Imel EA, et al. Burosumab versus conventional therapy in children with X‑linked hypophosphataemia: a randomised, active-controlled, open-label, phase 3 trial. Lancet. 2019;393(10189):2416–27. PubMedPubMedCentral
33.
Zurück zum Zitat Insogna KL, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X‑linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383–93. Insogna KL, et al. A randomized, double-blind, placebo-controlled, phase 3 trial evaluating the efficacy of burosumab, an anti-FGF23 antibody, in adults with X‑linked hypophosphatemia: week 24 primary analysis. J Bone Miner Res. 2018;33(8):1383–93.
34.
Zurück zum Zitat Portale AA, et al. Continued beneficial effects of burosumab in adults with X‑linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271–84. PubMed Portale AA, et al. Continued beneficial effects of burosumab in adults with X‑linked hypophosphatemia: results from a 24-week treatment continuation period after a 24-week double-blind placebo-controlled period. Calcif Tissue Int. 2019;105(3):271–84. PubMed
35.
Zurück zum Zitat Lowe D, Sanvictores T, John S. Alkaline phosphatase. Treasure Island (FL): StatPearls Publishing LLC; 2020. Lowe D, Sanvictores T, John S. Alkaline phosphatase. Treasure Island (FL): StatPearls Publishing LLC; 2020.
36.
Zurück zum Zitat Salles JP. Hypophosphatasia: biological and clinical aspects, avenues for therapy. Clin Biochem Rev. 2020;41(1):13–27. PubMedPubMedCentral Salles JP. Hypophosphatasia: biological and clinical aspects, avenues for therapy. Clin Biochem Rev. 2020;41(1):13–27. PubMedPubMedCentral
37.
Zurück zum Zitat Vogt M, et al. Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. Orphanet J Rare Dis. 2020;15(1):212. PubMedPubMedCentral Vogt M, et al. Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children. Orphanet J Rare Dis. 2020;15(1):212. PubMedPubMedCentral
38.
Zurück zum Zitat Choida V, Bubbear JS. Update on the management of hypophosphatasia. Ther Adv Musculoskelet Dis. 2019;11:1759720x19863997. PubMedPubMedCentral Choida V, Bubbear JS. Update on the management of hypophosphatasia. Ther Adv Musculoskelet Dis. 2019;11:1759720x19863997. PubMedPubMedCentral
39.
Zurück zum Zitat Kishnani PS, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149–62. PubMed Kishnani PS, et al. Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia. Bone. 2019;121:149–62. PubMed
40.
Zurück zum Zitat Bowden SA, Adler BH. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia. Osteoporos Int. 2018;29(2):511–5. PubMed Bowden SA, Adler BH. Asfotase alfa treatment for 1 year in a 16 year-old male with severe childhood hypophosphatasia. Osteoporos Int. 2018;29(2):511–5. PubMed
41.
Zurück zum Zitat Hofmann C, Seefried L, Jakob F. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc). 2016;52(5):271–85. Hofmann C, Seefried L, Jakob F. Asfotase alfa: enzyme replacement for the treatment of bone disease in hypophosphatasia. Drugs Today (Barc). 2016;52(5):271–85.
42.
Zurück zum Zitat Whyte MP, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93–105. PubMed Whyte MP, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93–105. PubMed
43.
Zurück zum Zitat Whyte MP, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334–42. PubMed Whyte MP, et al. Asfotase alfa treatment improves survival for perinatal and infantile hypophosphatasia. J Clin Endocrinol Metab. 2016;101(1):334–42. PubMed
44.
Zurück zum Zitat Genest F, et al. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9):e10395. PubMedPubMedCentral Genest F, et al. Physical function and health-related quality of life in adults treated with asfotase alfa for pediatric-onset hypophosphatasia. JBMR Plus. 2020;4(9):e10395. PubMedPubMedCentral
45.
Zurück zum Zitat Simon S, et al. Hypophosphatasia: from diagnosis to treatment. Curr Rheumatol Rep. 2018;20(11):69. PubMed Simon S, et al. Hypophosphatasia: from diagnosis to treatment. Curr Rheumatol Rep. 2018;20(11):69. PubMed
46.
Zurück zum Zitat Magdaleno AL, et al. Adult-onset hypophosphatasia: before and after treatment with ASFOTASE ALFA. AACE Clin Case Rep. 2019;5(6):e344–e8. PubMedPubMedCentral Magdaleno AL, et al. Adult-onset hypophosphatasia: before and after treatment with ASFOTASE ALFA. AACE Clin Case Rep. 2019;5(6):e344–e8. PubMedPubMedCentral
47.
Zurück zum Zitat Klidaras P, et al. Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus. 2018;2(5):304–7. PubMedPubMedCentral Klidaras P, et al. Fracture healing in two adult patients with hypophosphatasia after asfotase alfa therapy. JBMR Plus. 2018;2(5):304–7. PubMedPubMedCentral
48.
Zurück zum Zitat Rolvien T, et al. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Bone. 2019;127:67–74. PubMed Rolvien T, et al. Recovery of bone mineralization and quality during asfotase alfa treatment in an adult patient with infantile-onset hypophosphatasia. Bone. 2019;127:67–74. PubMed
49.
Zurück zum Zitat Freitas TQ, Franco AS, Pereira RMR. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: case report. Medicine. 2018;97(48):e13210. PubMedPubMedCentral Freitas TQ, Franco AS, Pereira RMR. Improvement of bone microarchitecture parameters after 12 months of treatment with asfotase alfa in adult patient with hypophosphatasia: case report. Medicine. 2018;97(48):e13210. PubMedPubMedCentral
51.
Zurück zum Zitat Whyte MP, et al. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone. 2019;122:231–6. PubMed Whyte MP, et al. No vascular calcification on cardiac computed tomography spanning asfotase alfa treatment for an elderly woman with hypophosphatasia. Bone. 2019;122:231–6. PubMed
52.
Zurück zum Zitat Bowden SA, Adler BH. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int. 2018;29(9):2155–6. PubMed Bowden SA, Adler BH. Reappearance of hypomineralized bone after discontinuation of asfotase alfa treatment for severe childhood hypophosphatasia. Osteoporos Int. 2018;29(9):2155–6. PubMed
Metadaten
Titel
New therapeutic options for bone diseases
verfasst von
MD Assoc. Prof. PD Roland Kocijan
MD Judith Haschka
MD Julia Feurstein
MD Assoc. Prof. PD Jochen Zwerina
Publikationsdatum
29.01.2021
Verlag
Springer Vienna
Erschienen in
Wiener Medizinische Wochenschrift / Ausgabe 5-6/2021
Print ISSN: 0043-5341
Elektronische ISSN: 1563-258X
DOI
https://doi.org/10.1007/s10354-020-00810-w